Wafik S. El‐Deiry

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• Biomarker-Guided Strategies for Tumor Vasculature: From Imaging Advances to Novel Therapeutic Interventions

  Cancer Letters · 2026-05-01

• Clinical outcomes with immune checkpoint inhibitor and/or enfortumab vedotin in patients with MTAP-deleted metastatic urothelial carcinoma.

  Journal of Clinical Oncology · 2026-03-01

• Table 3 from BrUOG360: A Phase Ib/II Study of Copanlisib in Combination with Rucaparib in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)

  2025-12-10

• Supplementary Table S1 from BrUOG360: A Phase Ib/II Study of Copanlisib in Combination with Rucaparib in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)

  2025-12-10

• Figure 1 from BrUOG360: A Phase Ib/II Study of Copanlisib in Combination with Rucaparib in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)

  2025-12-10

• Figure 2 from BrUOG360: A Phase Ib/II Study of Copanlisib in Combination with Rucaparib in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)

  2025-12-10

• Data from BrUOG360: A Phase Ib/II Study of Copanlisib in Combination with Rucaparib in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)

  2025-12-10

• Table 2 from BrUOG360: A Phase Ib/II Study of Copanlisib in Combination with Rucaparib in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)

  2025-12-10

• Table 1 from BrUOG360: A Phase Ib/II Study of Copanlisib in Combination with Rucaparib in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)

  2025-12-10

• Supplementary Table S2 from BrUOG360: A Phase Ib/II Study of Copanlisib in Combination with Rucaparib in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)

  2025-12-10

• Cellular senescence: A novel mechanism of therapeutic resistance in prostate cancer

  Cancer Treatment Reviews · 2025-11-28 · 3 citations

• Corrigendum to “P53-independent partial restoration of the p53 pathway in tumors with mutated p53 through ATF4 transcriptional modulation by ERK1/2 and CDK9” [Neoplasia, volume 23 (2021) 304325]

  Neoplasia · 2025-11-19

• The evolving landscape of antibody-drug conjugates (ADCs) for treatment of prostate cancer

  npj Precision Oncology · 2025-11-14 · 12 citations

• BrUOG360: A Phase Ib/II Study of Copanlisib in Combination with Rucaparib in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)

  Cancer Research Communications · 2025-11-13

• IMMU-21. Antiviral Therapy Reverses CMV-Induced Oncogenic Signaling and Enhances NK Cell Cytotoxicity in Glioblastoma with Associated PD-L1 Upregulation and Immune Modulation

  Neuro-Oncology · 2025-11-01

• DDEL-32. An atlas of ex vivo drug sensitivity profiles in 666 clinical glioblastoma samples revealed distinct survival-associated networks

  Neuro-Oncology · 2025-11-01

• Feedforward miR-181d degradation modulates population variance of methyl-guanine methyl transferase and temozolomide resistance

  Cell Reports · 2025-11-01 · 4 citations

• 913 Reprogramming the tumor immune microenvironment: STING activation synergies with BRAF inhibition to boost NK-mediated cytotoxicity in BRAF V600E mutant melanoma

  Regular and Young Investigator Award Abstracts · 2025-11-01

• DNAR-03. ONC201 synergizes with concurrent temozolomide-radiotherapy against newly diagnosed glioblastomas

  Neuro-Oncology · 2025-11-01

• DDEL-24. Investigating GSK3 Inhibition as a Strategy to Modulate the Blood-Brain Barrier and Enhance Drug Uptake in Pediatric Diffuse High-Grade Glioma Models

  Neuro-Oncology · 2025-11-01